Prognostic value of c-Met in colorectal cancer: A meta-analysis

被引：62

作者：

Liu, Yan ^{[1
]}

Yu, Xiao-Feng ^{[1
]}

Zou, Jian ^{[1
]}

Luo, Zi-Hua ^{[1
]}

机构：

[1] Fudan Univ, Huadong Hosp, Dept Gastroenterol, Shanghai 200040, Peoples R China

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2015年 / 21卷 / 12期

关键词：

Colorectal cancer; Prognosis; c-Met; Meta-analysis; Overall survival; HEPATOCYTE GROWTH-FACTOR; II COLON-CANCER; CLINICAL-SIGNIFICANCE; LIVER METASTASES; EXPRESSION; STAGE; RECEPTOR; OVEREXPRESSION; AMPLIFICATION; COEXPRESSION;

D O I：

10.3748/wjg.v21.i12.3706

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

AIM: To assess the prognostic value of c-Met status in colorectal cancer. METHODS: We conducted a search in PubMed, Web of Science, and the Cochrane Library covering all published papers up to July 2014. Only studies assessing survival in colorectal cancer by c-Met status were included. This meta-analysis was performed by using STATA11.0. RESULTS: Ultimately, 11 studies were included in this analysis. Meta-analysis of the hazard ratios (HR) indicated that patients with high c-Met expression have a significantly poorer overall survival (OR) (HR = 1.33, 95% CI: 1.06-1.59) and progression-free survival (PFS) (HR = 1.47, 95% CI: 1.03-1.91). Subgroup analysis showed a significant association between high c-Met expression and poorer overall survival in the hazard ratio reported (HR = 1.41, 95% CI: 1.08-1.74). CONCLUSION: The present meta-analysis indicated that high c-Met expression was associated with poor prognosis in patients with colorectal cancer.

引用

页码：3706 / 3710

页数：5

共 26 条

[1] Significance of micrometastases in colorectal cancer [J].

Feezor, RJ ;

Copeland, EM ;

Hochwald, SN .

ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (10) :944-953

[2] Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases [J].

Fujita, S ;

Sugano, K .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (06) :378-383

[3] FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk [J].

Garouniatis, Alexandros ;

Zizi-Sermpetzoglou, Adamantia ;

Rizos, Spyros ;

Kostakis, Alkiviadis ;

Nikiteas, Nikolaos ;

Papavassiliou, Athanasios G. .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2013, 28 (01) :9-18

[4] The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer [J].

Ginty, Fiona ;

Adak, Sudeshna ;

Can, Ali ;

Gerdes, Michael ;

Larsen, Melinda ;

Cline, Harvey ;

Filkins, Robert ;

Pang, Zhengyu ;

Li, Qing ;

Montalto, Michael C. .

CLINICAL CANCER RESEARCH, 2008, 14 (12) :3814-3822

[5] Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer? [J].

Inno, Alessandro ;

Di Salvatore, Mariantonietta ;

Cenci, Tonia ;

Martini, Maurizio ;

Orlandi, Armando ;

Strippoli, Antonia ;

Ferrara, Anna Maria ;

Bagala, Cinzia ;

Cassano, Alessandra ;

Larocca, Luigi Maria ;

Barone, Carlo .

CLINICAL COLORECTAL CANCER, 2011, 10 (04) :325-332

[6]

ITZKOWITZ SH, 1990, CANCER-AM CANCER SOC, V66, P1960, DOI 10.1002/1097-0142(19901101)66:9<1960::AID-CNCR2820660919>3.0.CO

[7]

2-X

[8] Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome [J].

Kammula, Udal S. ;

Kuntz, Eleanor J. ;

Francone, Todd D. ;

Zeng, Zhaoshi ;

Shia, Jinru ;

Landmann, Ron G. ;

Paty, Philip B. ;

Weiser, Martin R. .

CANCER LETTERS, 2007, 248 (02) :219-228

[9]

Kim SJ, 2003, CLIN CANCER RES, V9, P5161

[10] Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS [J].

Kishiki, Tomokazu ;

Ohnishi, Hiroaki ;

Masaki, Tadahiko ;

Ohtsuka, Kouki ;

Ohkura, Yasuo ;

Furuse, Jyunji ;

Watanabe, Takashi ;

Sugiyama, Masanori .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) :749-757

← 1 2 3 →